- Home
- HOTH vs MTVA Comparison
HOTH vs MTVA Comparison
Compare HOTH & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- MTVA
- Stock Information
- Founded
- HOTH 2017
- MTVA 2014
- Country
- HOTH United States
- MTVA United States
- Employees
- HOTH N/A
- MTVA N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- HOTH Health Care
- MTVA
- Exchange
- HOTH Nasdaq
- MTVA NYSE
- Market Cap
- HOTH 8.3M
- MTVA 7.1M
- IPO Year
- HOTH 2019
- MTVA N/A
- Fundamental
- Price
- HOTH $0.86
- MTVA $0.68
- Analyst Decision
- HOTH Strong Buy
- MTVA Strong Buy
- Analyst Count
- HOTH 3
- MTVA 1
- Target Price
- HOTH $4.00
- MTVA $12.00
- AVG Volume (30 Days)
- HOTH 188.6K
- MTVA 222.8K
- Earning Date
- HOTH 05-12-2025
- MTVA 05-14-2025
- Dividend Yield
- HOTH N/A
- MTVA N/A
- EPS Growth
- HOTH N/A
- MTVA N/A
- EPS
- HOTH N/A
- MTVA N/A
- Revenue
- HOTH N/A
- MTVA N/A
- Revenue This Year
- HOTH N/A
- MTVA N/A
- Revenue Next Year
- HOTH N/A
- MTVA N/A
- P/E Ratio
- HOTH N/A
- MTVA N/A
- Revenue Growth
- HOTH N/A
- MTVA N/A
- 52 Week Low
- HOTH $0.58
- MTVA $0.71
- 52 Week High
- HOTH $3.80
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- HOTH 45.65
- MTVA N/A
- Support Level
- HOTH $0.87
- MTVA N/A
- Resistance Level
- HOTH $0.98
- MTVA N/A
- Average True Range (ATR)
- HOTH 0.06
- MTVA 0.00
- MACD
- HOTH 0.00
- MTVA 0.00
- Stochastic Oscillator
- HOTH 24.37
- MTVA 0.00
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.